Ledger. Australian venture funding, tracked

Startup · $333.2k raised

Anaxis Pharma

Targets cell death in diabetic kidney disease

Coverage

Stories naming Anaxis Pharma. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

14 deals

Life sciences investor MTPConnect injects $12 million into 14 drug and device startups

MTPConnect's government-backed accelerator program has awarded $12.07 million in non-dilutive grants to 14 Australian drug and device companies, which will also receive mentoring and support from partners including CSL and Roche Diagnostics.

Startup Daily 23 Jun 2025 Anaxis PharmaArgenica TherapeuticsAspectheraAtherid TherapeuticsCathRx LtdEndo AxiomI D & EInosi TherapeuticsNanomedxProGenis PharmaceuticalsTheia MedicalVenstra MedicalWavewise AnalyticsZiP DiagnosticsCSLMedical Research Future FundMTPConnectStuart Dignam

Also SmartCompany·@AuManufacturing

Funding announcement

Professor got nothing from the $2.8b sale of his molecule, and that's okay

Profile of scientist-entrepreneur Andrew Wilks covering the GSK sale of his cancer molecule, his SYNthesis BioVentures fund's family-office backers, and portfolio plays including Aculeus Therapeutics.

Forbes Australia 17 Oct 2024 Aculeus Therapeutics Pty LtdAnaxis PharmaCytopiaGSKHarvardLudwig Institute for Cancer ResearchMerckNovartisPeter MacCallum Cancer CentrePFD Food ServicesPfizerProfessor Andrew WilksProject XSkin2NeuronSYNthesis BioVenturesSYNthesis GroupSynthesis MedchemSYNthesis ResearchUniversity of New South WalesWalter and Eliza Hall InstituteTaysideProf Andrew WilksProfessor Andrew F Wilks
Fund close $20m

Scientist behind Australia’s highest-priced molecule reveals how to profit from early stage biotechs

Biotech scientist Andrew Wilks launches fund SYNthesis BioVentures, which has gathered $20m and aims for $75m; his group has backed two biotech startups and he earlier sold a chemistry business to Viva Biotech.

Synthesis BioVentures 5 Sep 2023 SYNthesis BioVenturesAculeus Therapeutics Pty LtdAnaxis PharmaGSKMerckPfizerServierSYNthesis GroupSYNthesis Med ChemAmir ZalcensteinProf Andrew Wilks

Something wrong? Tell us